Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 30

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 30
---
 sustainability efforts and have documented our initiatives in our 2024 ESG Report, which is available on our website at ir.pmvpharma.com. The content provided in our 2024 ESG Report or accessible through our website is not part of our proxy solicitation materials.

17

TABLE OF CONTENTS

EXECUTIVE OFFICERS The following table sets forth certain information about our executive officers as of the date of this proxy statement. Information regarding Dr. Mack, who also serves as a director, is set forth above under “ Board of Directors and Corporate Governance—Continuing Directors.”

| Name                     |     | Age |     | Position(s)                                     |
| David H. Mack, Ph.D.     |     |  63 |     | President, Chief Executive Officer and Director |
| Michael Carulli          |     |  51 |     | Chief Financial Officer                         |
| Deepika Jalota, Pharm.D. |     |  49 |     | Chief Development Officer                       |
| Robert Ticktin           |     |  63 |     | General Counsel and Chief Operating Officer     |

Michael Carulli has served as our Chief Financial Officer since January 2024. Prior to being promoted as our Chief Financial Officer, Mr. Carulli served as our Senior Vice President of Finance from March 2023 to January 2024 and as Vice President of Finance from May 2020 to March 2023. Before joining PMV Pharmaceuticals, from May 2010 to May 2020, Mr. Carulli worked at Celgene Corporation, a global biopharmaceutical company, where he held multiple positions, including as Executive Director FP&A – Research & Development. Mr. Carulli received a B.S. in Marketing and Management from Siena College and a M.B.A. from the Fordham Gabelli School of Business. Deepika Jalota, Pharm.D. has served as our Chief Development Officer since May 2023. Prior to being promoted as our Chief Development Officer, Dr. Jalota served as our Chief Regulatory and Quality Officer from February 2021 to May 2023 and also previously served as our Senior Vice President, Regulatory Affairs and Quality Assurance from June 2019 to February 2021. Before joining PMV Pharmaceuticals, Dr. Jalota was employed by Bayer HealthCare Pharmaceuticals from July 2007 to May 2019 and held multiple leadership positions within Global Regulatory Affairs in oncology and other therapeutic areas. She was most recently Vice President, Global Regulatory